MCID: PST005
MIFTS: 54

Posterior Uveitis

Categories: Eye diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Posterior Uveitis

MalaCards integrated aliases for Posterior Uveitis:

Name: Posterior Uveitis 12 74 52 58 15 17
Uveitis, Posterior 12 74 43 71
Uveitis Posterior 54
Choroiditis 58

Characteristics:

Orphanet epidemiological data:

58
posterior uveitis
Inheritance: Not applicable; Age of onset: All ages; Age of death: normal life expectancy;

Classifications:

Orphanet: 58  
Rare eye diseases


External Ids:

Disease Ontology 12 DOID:12574
MeSH 43 D015866
NCIt 49 C35111
SNOMED-CT 67 43363007
ICD10 via Orphanet 33 H30.0 H30.1 H30.2 more
UMLS via Orphanet 72 C0008526 C0042167
Orphanet 58 ORPHA280892
UMLS 71 C0042167

Summaries for Posterior Uveitis

MalaCards based summary : Posterior Uveitis, also known as uveitis, posterior, is related to birdshot chorioretinopathy and choroiditis, and has symptoms including eye manifestations An important gene associated with Posterior Uveitis is IL2RA (Interleukin 2 Receptor Subunit Alpha), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Methylprednisolone and Prednisolone phosphate have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and endothelial, and related phenotypes are homeostasis/metabolism and hematopoietic system

Wikipedia : 74 Uveitis is the inflammation of the uvea, the pigmented layer that lies between the inner retina and the... more...

Related Diseases for Posterior Uveitis

Diseases in the Uveitis family:

Autoimmune Uveitis Posterior Uveitis
Intermediate Uveitis Infectious Anterior Uveitis
Infectious Posterior Uveitis Systemic Diseases with Anterior Uveitis
Systemic Diseases with Posterior Uveitis

Diseases related to Posterior Uveitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1978)
# Related Disease Score Top Affiliating Genes
1 birdshot chorioretinopathy 32.1 RBP3 MRAP CCR6
2 choroiditis 31.4 TNF SAG RBP3 MRAP IFNG CFH
3 multifocal choroiditis 31.3 TNF CFH
4 retinal vasculitis 31.2 TNF SAG RBP3 MRAP CCR6
5 chorioretinitis 31.2 TNF SAG RBP3 MRAP IL6 IL2
6 sympathetic ophthalmia 30.7 TNF RBP3 LTA
7 retinal detachment 30.7 TNF LTA IL6 IFNG CAPN5
8 macular retinal edema 30.6 TNF MRAP IL6
9 toxoplasmosis 30.6 TNF IL6 IL5 IL4 IFNG
10 optic neuritis 30.5 TNF LTA IL6 IL2RA
11 neuritis 30.5 TNF IL6 IL4 IFNG
12 familial mediterranean fever 30.4 TNF IL6 IL1A
13 poems syndrome 30.4 TNF IL6 IL2
14 cytokine deficiency 30.4 IL9 IL5 IL13
15 bacterial meningitis 30.4 TNF IL6 IFNG
16 lyme disease 30.3 TNF IL6 CFH
17 keratopathy 30.3 TNF IL4 IL1A
18 cone-rod dystrophy 2 30.3 TNF SAG RBP3 LTA IL6 IL2
19 poliomyelitis 30.2 TNF IL4 IFNG
20 iridocyclitis 30.2 TNF RBP3 MRAP IL6
21 alopecia 30.2 TNF IL4 IL2 IFNG
22 obstructive jaundice 30.1 TNF IL6 IL2
23 histiocytosis 30.1 TNF IFNG CCR6
24 measles 30.1 TNF IL6 IL2RA IL2 IFNG
25 neutropenia 30.1 TNF IL6 IL2 IFNG
26 endocarditis 30.0 TNF IL6 IL1A IFNG
27 neuroretinitis 30.0 SAG MRAP
28 purpura 30.0 TNF IL6 IL4 IFNG
29 hepatitis a 30.0 TNF IL4 IFNG
30 churg-strauss syndrome 29.9 TNF IL5 IL2
31 brucellosis 29.9 TNF IL6 IL4 IL2 IL13 IFNG
32 progressive multifocal leukoencephalopathy 29.9 TNF IL2 CCR6
33 stomatitis 29.9 TNF IL6 IL4 IL2 IFNG
34 pneumocystosis 29.9 TNF IL6 CCR6
35 mumps 29.9 TNF IL6 IL2RA IL2 IFNG
36 herpes zoster 29.9 TNF IL2 IFNG CCR6
37 chronic graft versus host disease 29.9 IL2RA IL1A IFNG
38 nervous system disease 29.9 TNF IL6 IFNG CCR6
39 eales disease 29.9 TNF SAG RBP3 IL6 IL4 IFNG
40 thymoma 29.9 TNF IL6 IL4 IL2
41 cutaneous lupus erythematosus 29.9 TNF IL6 IFNG
42 meningoencephalitis 29.9 TNF IL6 IL4 CCR6
43 cardiac sarcoidosis 29.8 TNF IL5 IFNG
44 blastomycosis 29.8 TNF IL6 CCR6
45 myocarditis 29.8 TNF IL6 IL4 IL2 IFNG
46 aseptic meningitis 29.8 TNF IL1A IFNG
47 extrapulmonary tuberculosis 29.8 TNF IL1A IFNG
48 brain edema 29.8 IL6 IL2 IFNG
49 dry eye syndrome 29.8 TNF IL6 CCR6
50 temporal arteritis 29.8 TNF IL6 IFNG CCR6

Graphical network of the top 20 diseases related to Posterior Uveitis:



Diseases related to Posterior Uveitis

Symptoms & Phenotypes for Posterior Uveitis

UMLS symptoms related to Posterior Uveitis:


eye manifestations

MGI Mouse Phenotypes related to Posterior Uveitis:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.3 CCR6 CFH IFNG IL13 IL1A IL2
2 hematopoietic system MP:0005397 10.28 CCR6 CFH IFNG IL13 IL1A IL2
3 growth/size/body region MP:0005378 10.25 CAPN5 CFH IFNG IL13 IL2 IL2RA
4 immune system MP:0005387 10.22 CAPN5 CCR6 CFH IFNG IL13 IL1A
5 cardiovascular system MP:0005385 10.19 CCR6 CFH IFNG IL1A IL2 IL2RA
6 endocrine/exocrine gland MP:0005379 10.16 IFNG IL13 IL2 IL2RA IL2RB IL4
7 digestive/alimentary MP:0005381 10.13 IFNG IL13 IL2 IL2RA IL4 IL5
8 mortality/aging MP:0010768 10 CAPN5 CFH IFNG IL13 IL2 IL27
9 liver/biliary system MP:0005370 9.91 IFNG IL2 IL2RB IL4 IL5 IL6
10 respiratory system MP:0005388 9.65 IFNG IL13 IL2 IL2RA IL4 IL5
11 vision/eye MP:0005391 9.36 CFH IFNG IL2 IL2RA IL4 IL6

Drugs & Therapeutics for Posterior Uveitis

Drugs for Posterior Uveitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 99)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
2
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
3
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
4 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
5
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
6
Chlorambucil Approved Phase 4 305-03-3 2708
7
Mycophenolic acid Approved Phase 4 24280-93-1 446541
8
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
9
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
10
Azathioprine Approved Phase 4 446-86-6 2265
11
Infliximab Approved Phase 4 170277-31-3
12
Ranibizumab Approved Phase 4 347396-82-1 459903
13
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 444795 5538
14
Choline Approved, Nutraceutical Phase 4 62-49-7 305
15
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
16 Methylprednisolone Acetate Phase 4
17 Cyclosporins Phase 4
18 Calcineurin Inhibitors Phase 4
19 Angiogenesis Inhibitors Phase 4
20 Alkylating Agents Phase 4
21 Laxatives Phase 4
22 Cathartics Phase 4
23 Carboxymethylcellulose Sodium Phase 4
24 Cytidine Diphosphate Choline Phase 4
25 Adrenocorticotropic Hormone Phase 4
26 Melanocyte-Stimulating Hormones Phase 4
27 beta-Endorphin Phase 4
28
Adalimumab Approved Phase 3 331731-18-1 16219006
29
Phenylephrine Approved Phase 3 59-42-7 6041
30
Fluorometholone Approved, Investigational Phase 3 426-13-1 9878
31
Oxymetazoline Approved, Investigational Phase 3 1491-59-4 4636
32
Rifampicin Approved Phase 3 13292-46-1 5381226 5458213
33
Ethambutol Approved Phase 3 74-55-5 3279 14052
34
Dipivefrin Approved Phase 3 52365-63-6 3105
35
Pyrazinamide Approved, Investigational Phase 3 98-96-4 1046
36
Tropicamide Approved, Investigational Phase 3 1508-75-4 5593
37
Atropine Approved, Vet_approved Phase 3 51-55-8, 5908-99-6 174174
38
Isoniazid Approved, Investigational Phase 3 54-85-3 3767
39 Interferon alpha-2 Phase 3
40 interferons Phase 3
41 Interferon-alpha Phase 3
42 Antiviral Agents Phase 3
43 Anti-Infective Agents Phase 3
44 Antitubercular Agents Phase 3
45 Anti-Bacterial Agents Phase 3
46 Ophthalmic Solutions Phase 3
47 Mydriatics Phase 3
48 Isoniazid, pyrazinamide, rifampin drug combination Phase 3
49 Immunoglobulins Phase 3
50 Antibodies Phase 3

Interventional clinical trials:

(show top 50) (show all 96)
# Name Status NCT ID Phase Drugs
1 The Efficacy of Intravenous Pulses of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's Disease, a Double Blind Pilot Study Unknown status NCT01306955 Phase 4 methylorednisolone
2 A Multi-Center, Prospective Single Arm Study to Assess the Efficacy and Safety of RETISERT (Intravitreal Flucinolone Acetonide 0.59mg) in Patients With Refractory Ocular Behcet's Disease Unknown status NCT00720928 Phase 4 flucinolone acetonide
3 Proof of Concept Study of the Effectiveness of Ozurdex in Lieu of Oral Corticosteroids for the Control of Active Intermediate and Posterior Uveitis Requiring Immunosuppressive Drug Therapy Completed NCT02049476 Phase 4 Dexamethasone pellet
4 Multicenter Uveitis Steroid Treatment (MUST) Trial Completed NCT00132691 Phase 4 fluocinolone acetonide intraocular implant;oral corticosteroid with immunosuppressive agents as needed
5 Prospective Open Label Study of H.P. Acthar Gel Injection in Patients With Active Non-Infectious Uveitis With Associated Glaucoma Thus High Frequency Regional Corticosteroid and Oral Corticosteroids Cause Intolerable Side-Effects Completed NCT02764697 Phase 4 H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
6 The Effects of BAK on the Blood Aqueous Barrier of Pseudophakic Patients Completed NCT01280110 Phase 4 Hydroxypropylmethylcellulose;Carboxymethylcellulose
7 TAHOE: Sustained InTravitreal DexAmetHasone Implant (Ozurdex) for Uveitic Macular Edema Completed NCT01870440 Phase 4 Ozurdex Intravitreal Injection (0.7 mg)
8 A Study to Investigate the Safety and Efficacy of Lucentis (Ranibizumab) in Patients With CNV Due to Causes Other Than AMD and in Patients Where Pigment Epithelial Detachments Are the Primary Manifestation of Their AMD. Completed NCT01628354 Phase 4 Ranibizumab
9 Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) : Pattern Electroretinography Study Completed NCT03046693 Phase 4 Group A Citicoline 1000 mg oral tablet;Group B placebo oral tablet
10 Open-label, Single-center, Prospective Study on the Efficacy and Safety of Repository Corticotropin Injection (H.P. ACTHAR GEL) in the Treatment of Adults With Non-infectious Retinal Vasculitis Recruiting NCT03066869 Phase 4 H.P. ACTHAR GEL
11 A Multicenter, Open Label Pilot Study to Explore the Efficacy and Safety of Acthar Gel in Subjects With Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis (NIPPU) Suspended NCT03656692 Phase 4 Acthar Gel
12 Posterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic Cystoid Macular Edema (CME) Withdrawn NCT02598869 Phase 4 Triamcinolone Acetonide
13 A Multi-center, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in Subjects With Chronic Non-infectious Uveitis Affecting the Posterior Segment of the Eye Unknown status NCT02746991 Phase 3 Sham Injection;FAI Insert
14 A Double-Masked, Placebo-Controlled, Multi-Center, Parallel-Group, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Clinically Quiescent Sight Threatening, Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis Completed NCT00404742 Phase 3 Placebo;LX211;LX211;LX211
15 A Double-Masked, Placebo-Controlled, Parallel Group, Multi-Center, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis Completed NCT00404612 Phase 3 Placebo;LX211;LX211;LX211
16 A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis Completed NCT00333814 Phase 2, Phase 3 Dexamethasone;dexamethasone;Sham injection
17 A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Inactive Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis - Including a Sub-study in Japanese Patients Completed NCT01124838 Phase 3 Adalimumab;Prednisone;Placebo
18 Open-label Safety Study of Suprachoroidal Triamcinolone Acetonide Injectable Suspension in Patients With Non-Infectious Uveitis Completed NCT03097315 Phase 3
19 A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis Completed NCT01148225 Phase 3 adalimumab
20 A Multicenter, Randomized, Double-Masked, Controlled Study to Evaluate the Safety & Efficacy of Intravitreal Fluocinolone Acetonide (0.59 or 2.1 mg) Implant in Subjects With Non-Infectious Uveitis Affecting the Posterior Segment of the Eye Completed NCT00407082 Phase 2, Phase 3 fluocinolone acetonide intravitreal implant;Fluocinolone acetonide 2.1mg
21 A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab as Maintenance Therapy in Subjects Requiring High Dose Corticosteroids for Active Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis - Including a Sub-study in Japanese Patients Completed NCT01138657 Phase 3 Prednisone;Placebo
22 A Phase 3, Randomized, Masked, Controlled Clinical Trial to Study the Safety and Efficacy of Triamcinolone Acetonide Injectable Suspension (CLS-TA) for the Treatment of Subjects With Macular Edema Associated With Non-infectious Uveitis Completed NCT02595398 Phase 3 4mg CLS-TA Suprachoriodal Injection;Sham Procedure
23 Phase III Study of Recombinant Human Interferon-alpha2a Versus Cyclosporin A for the Treatment of Ocular Behcet`s Disease - a National,Randomised, Single-masked Controlled Trial (INCYTOB) Completed NCT00167583 Phase 3 Cyclosporin A;Interferon-alpha2a
24 A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye Completed NCT01358266 Phase 3 DE-109 44 ug;DE-109 440 ug;DE-109 880 ug
25 A 24 Week Multicenter, Randomized, Double-masked, Placebo Controlled Study to Assess the Difference in the Rate of Recurrent Exacerbations in Behçet¿s Patients With Posterior or Panuveitis Treated With AIN457 vs Placebo Adjunctive to Standard-of-care Immunosuppressive Therapy Completed NCT00995709 Phase 3 AIN457;AIN457;Placebo
26 Intravitreal Bevacizumab for the Treatment of Neovascular Membranes in Patients With Intraocular Inflammation Completed NCT00407121 Phase 3 Bevacizumab
27 Multicenter, Randomized Study Evaluating the Value of Antitubercular Treatment During Recurent Anterior Uveitis (URBA) Not yet recruiting NCT04117698 Phase 3 Antitubercular treatment (RIFATER ©);Ethambutol;RIFINAH ©
28 A Safety Open-label Study of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis Disease, an eXtension Study. The EYEGUARD-X Study Terminated NCT02375685 Phase 3
29 A 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior or Panuveitis Requiring Immunosuppression (INSURE Study) Terminated NCT01095250 Phase 3 AIN457;AIN457;AIN457;Placebo
30 An Open-Label, Non-Randomized, Single-Arm, Rollover Study to Continue Dosing of Gevokizumab in Subjects With Non Infectious Intermediate-, Posterior-, or Pan-Uveitis Patients Who Each Successfully Completed Either the X052130/CL3-78989-005 (EYEGUARD™-A) or the X052131/CL3-78989-006 (EYEGUARD™-C) Study or Who Have Controlled Ocular Inflammation After Receiving Study Drug in Study X052133 (EYEGUARD™-US) Terminated NCT02258854 Phase 3 Dose 2 gevokizumab
31 A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Subjects With Non-infectious Intermediate, Posterior, or Pan-uveitis Currently Controlled With Systemic Treatment Terminated NCT01747538 Phase 3 Placebo;Dose 1 gevokizumab;Dose 2 gevokizumab
32 A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis Terminated NCT01684345 Phase 3 Placebo;Dose 1 gevokizumab;Dose 2 gevokizumab
33 A 24 Week Multi-center, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis. Terminated NCT01032915 Phase 3 Placebo
34 A 34-week Extension to a 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior, or Panuveitis Requiring Immunosuppression (INSURE Study) Terminated NCT01103024 Phase 3
35 A 38-week Extension to a 24-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis Terminated NCT01090310 Phase 3 AIN457;Placebo
36 A Multicenter, Open-label Study to Evaluate the Long Term Clinical Use of Treatment With AIN457 in Patients Completing Clinical Trials Investigating AIN457 for the Treatment of Non-infectious Intermediate, Posterior or Panuveitis Withdrawn NCT01327664 Phase 3
37 Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study Unknown status NCT01717170 Phase 1, Phase 2 Tocilizumab
38 A Multicenter, Single Sequence, Open-label Study to Assess the Tolerability, Safety, and Efficacy of 2 Weeks Oral AEB071 300 mg Twice Daily, Followed by 6 Weeks AEB071 200 mg Twice Daily in the Treatment of Patients With Macular Edema Associated With Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis Completed NCT00615693 Phase 2 AEB071
39 Open-Label, Safety and Tolerability Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle in Subjects With Non-Infectious Uveitis Completed NCT01789320 Phase 1, Phase 2 triamcinolone acetonide (Triesence®)
40 A Randomized, Masked, Multicenter Study to Assess the Safety and Efficacy of CLS-TA, Triamcinolone Acetonide Injectable Suspension in the Treatment of Subjects With Macular Edema Following Uveitis Completed NCT02255032 Phase 2 4 mg CLS-TA;0.8 mg CLS-TA
41 Combination Daclizumab/Denileukin Diftitox (Ontak) Therapy for the Induction of Immune Tolerance in Non-infectious Intermediate and Posterior Uveitis Completed NCT00326508 Phase 2 Daclizumab
42 A Randomized, Active-controlled, Open-label, Multicenter proof-of Concept Study of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, Posterior-, or Panuveitis Requiring Systemic Immunosuppressive Therapy Completed NCT01526889 Phase 2 LFG316;Conventional Therapy
43 An Open-label Proof-of-concept Study With a Double-masked, Dose-ranging Component to Assess the Effects of AIN457 in Patients With Noninfectious Uveitis Completed NCT00685399 Phase 2 AIN457;AIN 457;AIN457
44 Research Study in Patients With Persistent Macular Edema Due to Diabetic Retinopathy, Retinal Vein Occlusion, Uveitis, or Irvine-Gass Syndrome Completed NCT00035906 Phase 2 DEX PS DDS®
45 Evaluation of Birdshot RETINE CHOROIDOPATHY Treatment by Either Steroid or Interferon alpha2a Completed NCT00508040 Phase 2 interferon alpha 2a;prednisone
46 Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy With Intravitreal Injection of Lucentis (Ranibizumab Injection) Completed NCT00470977 Phase 1, Phase 2 ranibizumab injection (0.5 mg)
47 Intravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical Study Completed NCT02620618 Phase 1, Phase 2 Intravitreal Infliximab
48 Daclizumab for Active, Non-infectious, Sight-threatening Uveitis: A Phase II Pilot Study Completed NCT00070759 Phase 2 Daclizumab
49 A Pilot Study to Investigate Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis Recruiting NCT02911116 Phase 2 Ustekinumab;Ustekinumab
50 Sirolimus as a Therapeutic Approach for Uveitis: A Phase 2, Open-label, Randomized Study to Assess the Safety, Tolerability, and Bioactivity of Two Doses of Intravitreal Injection of Sirolimus in Patients With Non-infectious Uveitis Recruiting NCT01280669 Phase 2 Intravitreal injection 440mcg;Intravitreal injection of sirolimus 880mcg

Search NIH Clinical Center for Posterior Uveitis

Cochrane evidence based reviews: uveitis, posterior

Genetic Tests for Posterior Uveitis

Anatomical Context for Posterior Uveitis

MalaCards organs/tissues related to Posterior Uveitis:

40
Eye, Retina, Endothelial, T Cells, Testes, B Cells, Brain

Publications for Posterior Uveitis

Articles related to Posterior Uveitis:

(show top 50) (show all 1356)
# Title Authors PMID Year
1
Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. 61 54
15878055 2005
2
Serum cytokine receptor levels in noninfectious uveitis. 54 61
15746567 2005
3
Human S-antigen: peptide determinant recognition in uveitis patients. 61 54
15010290 2004
4
Human retinal S-antigen: T cell epitope mapping in posterior uveitis patients. 54 61
11263956 2001
5
Oligoclonal activation of CD4+ T lymphocytes in posterior uveitis. 54 61
7882564 1995
6
[Cellular immunoreaction to S-antigen in patients with uveitis and optic neuritis]. 54 61
8223035 1993
7
Distribution of IL-2R and CD45Ro expression on CD4+ and CD8+ T-lymphocytes in the peripheral blood of patients with posterior uveitis. 61 54
1358556 1992
8
Identification of an S-antigen-like molecule in human choroid plexus and cerebrospinal fluid. 61 54
1289136 1992
9
Seronegative ocular toxoplasma panuveitis in an immunocompetent patient. 61
32566798 2020
10
Clinical utility of aqueous humor polymerase chain reaction and serologic testing for suspected infectious uveitis: a single-center retrospective study in South Korea. 61
32560636 2020
11
Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet's syndrome. 61
32157555 2020
12
Case Report: Posterior Uveitis after Divalent Human Papillomavirus Vaccination in an Asian Female. 61
32511159 2020
13
Yellow Sub-Retinal Pigment Epithelium (YSRPE) Deposits: A Novel Sign in Ocular Tuberculosis. 61
32541431 2020
14
Oscillatory potentials in patients with birdshot chorioretinopathy. 61
32542469 2020
15
Severe acute multi-systemic failure with bilateral ocular toxoplasmosis in immunocompetent patients from urban settings in Colombia: Case reports. 61
32195446 2020
16
Pediatric Uveitis in a Referral Center in North Part of Turkey. 61
32463707 2020
17
Long-term Outcomes of Glaucoma Drainage Implants in Uveitic Eyes with Fluocinolone Acetonide Implants. 61
32404619 2020
18
Primary Vitreoretinal Lymphoma in HIV Infection. 61
32453669 2020
19
Ophthalmic involvement of chronic lymphocytic leukemia: a systematic review of 123 cases. 61
32407752 2020
20
Ocular manifestations in rheumatoid arthritis, connective tissue disease and vasculitis: a systematic review and meta-analysis. 61
32358156 2020
21
Local therapy for cancer therapy-associated uveitis: a case series and review of the literature. 61
31409649 2020
22
Epidemiology of 2000 Chinese uveitis patients from Northeast China. 61
32424058 2020
23
Multimodal imaging patterns of posterior syphilitic uveitis: a review of the literature, laboratory evaluation and treatment. 61
31927680 2020
24
Retinal Microcirculation Defects on OCTA Correlate with Active Inflammation and Vision in Vogt-Koyanagi-Harada Disease. 61
32407159 2020
25
Quantitative Analysis of the Choriocapillaris in Uveitis Using en face Swept Source Optical Coherence Tomography Angiography. 61
32413411 2020
26
[Toxoplasmosis and behavioural changes (French translation of the article)]. 61
32248961 2020
27
Efficacy and Safety of Intravitreal Sirolimus for Noninfectious Uveitis of the Posterior Segment: Results from the Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) Program. 61
32564920 2020
28
Vaccine-Associated Posterior Uveitis. 61
32221173 2020
29
Ocular syphilis in Pacific peoples-are we making misdiagnoses secondary to yaws? 61
32325468 2020
30
[Treatment of noninfectious intermediate uveitis, posterior uveitis, or panuveitis]. 61
31818505 2020
31
Characterization and Management of Inflammatory Eye Disease in Patients with Hidradenitis Suppurativa. 61
32255701 2020
32
Pattern and Outcome of Uveitis in a Tertiary Military Hospital in Thailand. 61
31009267 2020
33
Retinal endothelial cell phenotypic modifications during experimental autoimmune uveitis: a transcriptomic approach. 61
32183784 2020
34
Clinical Features and Visual Outcome of Uveitis in Japanese Patients Younger than 18 Years. 61
32162972 2020
35
Retinal vascular inflammatory and occlusive changes in infectious and non-infectious uveitis. 61
32016664 2020
36
Long-Term Outcomes of Treatment with Biological Agents in Eyes with Refractory, Active, Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. 61
31607412 2020
37
Recommendations statement on the immunosuppressive treatment of non-infectious, non-neoplastic, non-anterior uveitis. 61
32199631 2020
38
RETINAL FINDINGS IN PRESUMED INFECTIOUS POSTERIOR UVEITIS AND CORRELATION WITH POLYMERASE CHAIN REACTION RESULTS. 61
30601389 2020
39
Clinical and laboratory characteristics of ocular syphilis and neurosyphilis among individuals with and without HIV infection. 61
32220852 2020
40
Optical coherence tomography diagnostic signs in posterior uveitis. 61
31513851 2020
41
NONINFECTIOUS POSTERIOR UVEITIS: BRINGING EMERGING TREATMENTS TO THE FOREFRONT. 61
32108725 2020
42
Intravitreal dexamethasone implant as an alternative to systemic steroids as prophylaxis for uveitic cataract surgery: a randomized trial. 61
31320735 2020
43
Toxoplasmosis and behavioural changes. 61
31980266 2020
44
Ocular toxoplasmosis associated with up-regulation of miR-155-5p/miR-29c-3p and down-regulation of miR-21-5p/miR-125b-5p. 61
31945658 2020
45
Evolving Longitudinal Retinal Observations in a Cohort of Survivors of Ebola Virus Disease. 61
32134433 2020
46
Aetiology of posterior uveitis in a tertiary centre in Finland. 61
31273927 2020
47
Posterior uveitis secondary to an African grey parrot bite. 61
31712020 2020
48
The Detection of Occult Retinal Vasculitis on Fluorescein Angiography in Pediatric Uveitis. 61
31708487 2020
49
Automated measurement of leakage on wide-field angiography in the assessment of retinal vasculitis. 61
32009203 2020
50
Patterns of Uveitis in Egypt. 61
32068471 2020

Variations for Posterior Uveitis

Expression for Posterior Uveitis

Search GEO for disease gene expression data for Posterior Uveitis.

Pathways for Posterior Uveitis

Pathways related to Posterior Uveitis according to GeneCards Suite gene sharing:

(show top 50) (show all 71)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.14 TNF LTA IL9 IL6 IL5 IL4
2
Show member pathways
13.94 TNF LTA IL9 IL6 IL5 IL4
3
Show member pathways
13.73 TNF LTA IL9 IL6 IL5 IL4
4
Show member pathways
13.65 TNF LTA IL9 IL6 IL5 IL4
5
Show member pathways
13.5 TNF LTA IL9 IL6 IL5 IL4
6
Show member pathways
13.43 TNF LTA IL9 IL6 IL5 IL4
7
Show member pathways
13.38 TNF LTA IL9 IL6 IL5 IL4
8
Show member pathways
13.27 TNF IL4 IL2RB IL2RA IL2 IL1A
9
Show member pathways
13.04 TNF IL6 IL4 IL2RB IL2RA IL2
10 12.99 IL6 IL5 IL4 IL2RB IL2RA IL2
11
Show member pathways
12.95 TNF IL6 IL2RB IL2RA IL2 IL1A
12
Show member pathways
12.92 TNF LTA IL9 IL6 IL4 IL2RB
13
Show member pathways
12.92 TNF LTA IL9 IL6 IL5 IL4
14
Show member pathways
12.8 TNF LTA IL9 IL6 IL2 IL1A
15
Show member pathways
12.74 TNF IL9 IL6 IL5 IL4 IL2
16
Show member pathways
12.69 TNF IL4 IL2RA IL2 IFNG
17 12.69 TNF IL4 IL2RB IL2RA IL2 IFNG
18
Show member pathways
12.69 TNF IL6 IL5 IL4 IL2RB IL2RA
19
Show member pathways
12.59 IL5 IL2RA IL2 IL1A IL13 CAPN5
20
Show member pathways
12.58 IL9 IL6 IL5 IL4 IL2RB IL2RA
21 12.5 TNF LTA IL6 IL2RB IL2RA IL2
22
Show member pathways
12.5 TNF LTA IL6 IL2RB IL2RA IL2
23
Show member pathways
12.49 TNF IL6 IL5 IL4 IL13 IFNG
24
Show member pathways
12.44 TNF IL6 IL4 IL2 IFNG
25
Show member pathways
12.34 TNF IL6 IL1A IFNG
26
Show member pathways
12.32 TNF IL4 IL1A IFNG
27 12.29 TNF IL6 IL1A IFNG
28
Show member pathways
12.29 IL9 IL4 IL2RB IL2RA IL2
29
Show member pathways
12.27 TNF LTA IL9 IL6 IL5 IL4
30
Show member pathways
12.24 TNF IL6 IL4 IFNG
31 12.23 TNF IL6 IL1A IL13
32
Show member pathways
12.2 IL5 IL2RB IL2RA IL2
33
Show member pathways
12.18 IL5 IL2RA IL2 IL1A IL13
34 12.18 TNF IL6 IL4 IL2 IL1A IFNG
35
Show member pathways
12.14 IL2RB IL2RA IL2 IFNG
36 12.14 TNF IL6 IL4 IL1A IL13
37
Show member pathways
12.13 IL4 IL2RB IL2RA IL2 IFNG
38
Show member pathways
12.11 TNF LTA IL6 IL27 IL2 IFNG
39 12.07 TNF IL6 IL5 IL4 IL2RA IL1A
40 12.07 TNF IL6 IL5 IL4 IL2RB IL2RA
41 11.98 TNF IL6 IL1A IFNG
42 11.96 IL6 IL5 IL4 IL2 IL13 IFNG
43
Show member pathways
11.92 TNF IL5 IL4 IL2RA IL2 IFNG
44
Show member pathways
11.88 LTA IL4 IL2RB IL2RA IL2
45 11.87 TNF IL6 IL2 IFNG
46
Show member pathways
11.85 TNF IL6 IL2 IL1A IFNG
47 11.84 TNF IL6 IL5 IL4 IL13
48
Show member pathways
11.82 TNF IL2RB IL2RA IL2 IFNG
49 11.8 TNF IL6 IL1A
50 11.72 LTA IL5 IL4

GO Terms for Posterior Uveitis

Cellular components related to Posterior Uveitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 TNF RBP3 LTA IL9 IL6 IL5
2 external side of plasma membrane GO:0009897 9.65 TNF IL2RB IL2RA IL13 CCR6
3 extracellular space GO:0005615 9.44 TNF RBP3 LTA IL9 IL6 IL5
4 interleukin-2 receptor complex GO:0005893 9.16 IL2RB IL2RA

Biological processes related to Posterior Uveitis according to GeneCards Suite gene sharing:

(show all 46)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 10.1 IL9 IL6 IL5 IL4 IL2 IFNG
2 positive regulation of gene expression GO:0010628 10.05 TNF IL6 IL4 IL1A IL13 IFNG
3 MAPK cascade GO:0000165 9.98 TNF IL5 IL2RB IL2RA IL2
4 negative regulation of inflammatory response GO:0050728 9.93 IL4 IL2RA IL2 IL13
5 inflammatory response GO:0006954 9.86 TNF IL9 IL6 IL5 IL2RA IL27
6 positive regulation of smooth muscle cell proliferation GO:0048661 9.85 TNF IL6 IL13
7 positive regulation of phagocytosis GO:0050766 9.82 TNF IL2RB IFNG
8 positive regulation of interferon-gamma production GO:0032729 9.82 TNF LTA IL2
9 positive regulation of interleukin-6 secretion GO:2000778 9.81 TNF IL1A IFNG
10 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.8 IL4 IL2 IL1A
11 positive regulation of T cell proliferation GO:0042102 9.8 IL6 IL4 IL2RA IL2
12 positive regulation of cytokine secretion GO:0050715 9.77 TNF IL1A IFNG
13 positive regulation of JAK-STAT cascade GO:0046427 9.77 TNF IL6 IL5
14 humoral immune response GO:0006959 9.72 TNF LTA IL6 IFNG CCR6
15 positive regulation of T cell differentiation GO:0045582 9.71 IL4 IL2RA IL2
16 positive regulation of B cell proliferation GO:0030890 9.71 IL5 IL4 IL2 IL13
17 positive regulation of neuroinflammatory response GO:0150078 9.7 TNF IL6
18 positive regulation of podosome assembly GO:0071803 9.7 TNF IL5
19 positive regulation of glial cell proliferation GO:0060252 9.7 TNF LTA IL6
20 positive regulation of interleukin-10 secretion GO:2001181 9.69 IL4 IL13
21 positive regulation of mast cell degranulation GO:0043306 9.69 IL4 IL13
22 negative regulation of amyloid-beta clearance GO:1900222 9.69 TNF IFNG
23 regulation of regulatory T cell differentiation GO:0045589 9.69 IL2RA IL2 IFNG
24 positive regulation of isotype switching to IgG isotypes GO:0048304 9.68 IL4 IL2
25 positive regulation of MHC class II biosynthetic process GO:0045348 9.68 IL4 IFNG
26 negative regulation of lipid storage GO:0010888 9.68 TNF IL6
27 negative regulation of T-helper 17 cell differentiation GO:2000320 9.68 IL4 IL2
28 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.67 TNF IFNG
29 positive regulation of mononuclear cell migration GO:0071677 9.67 TNF IL4
30 microglial cell activation GO:0001774 9.67 TNF IL4 IL13 IFNG
31 negative regulation of lymphocyte proliferation GO:0050672 9.66 IL2RA IL2
32 positive regulation of cellular respiration GO:1901857 9.66 IL4 IFNG
33 neuroinflammatory response GO:0150076 9.65 IL4 IFNG
34 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.65 TNF LTA
35 positive regulation of chemokine biosynthetic process GO:0045080 9.65 TNF IL4 IFNG
36 positive regulation of immunoglobulin secretion GO:0051024 9.63 IL6 IL5 IL2
37 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.63 TNF IL6 IL4 IL2 IL13 IFNG
38 negative regulation of complement-dependent cytotoxicity GO:1903660 9.62 IL4 IL13
39 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.61 TNF IFNG
40 regulation of T cell homeostatic proliferation GO:0046013 9.61 IL2RA IL2
41 interleukin-2-mediated signaling pathway GO:0038110 9.61 IL2RB IL2RA IL2
42 cytokine-mediated signaling pathway GO:0019221 9.61 TNF IL6 IL5 IL4 IL2RB IL2RA
43 positive regulation of vitamin D biosynthetic process GO:0060557 9.57 TNF IFNG
44 positive regulation of nitrogen compound metabolic process GO:0051173 9.56 TNF IFNG
45 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 9.55 TNF LTA
46 immune response GO:0006955 9.4 TNF LTA IL9 IL6 IL5 IL4

Molecular functions related to Posterior Uveitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.36 TNF LTA IL9 IL6 IL5 IL4
2 growth factor activity GO:0008083 9.35 IL9 IL6 IL5 IL4 IL2
3 cytokine receptor binding GO:0005126 9.33 IL9 IL4 IL13
4 interleukin-2 binding GO:0019976 9.32 IL2RB IL2RA
5 interleukin-2 receptor activity GO:0004911 9.26 IL2RB IL2RA

Sources for Posterior Uveitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....